Charmacy Pharmaceutical 2025 Annual Report: Key Investor Insights

1. Financial Performance and Dividend Announcement

Charmacy Pharmaceutical Co., Ltd. has released its 2025 annual report, providing a comprehensive overview of its financial performance, business developments, and key decisions that could impact shareholder value.

• Net Profit: The Group reported a net profit of RMB 46.27 million for 2025, a decline from RMB 53.28 million in 2024. Basic and diluted earnings per share were both RMB 0.4285, down from RMB 0.4934 the previous year.
• Dividend Proposal: The Board recommends a final dividend of RMB 0.30 per share (tax inclusive) for 2025, subject to approval at the AGM scheduled for May 22, 2026. The total dividend payout is projected at RMB 32.4 million. H-shareholders will receive the dividend in RMB or HKD, depending on their share classification, with the HKD conversion rate based on the average RMB/HKD rate five business days before the AGM.
• Dividend Policy: The Company maintains a prudent dividend policy, considering operating results, cash flows, financial position, capital expenditure needs, and distributable profits under PRC GAAP and relevant laws.
• Reserves: As of December 31, 2025, distributable reserves stood at RMB 229.37 million, with unallocated profits at RMB 190.59 million.
• Cash Flow: Cash and cash equivalents increased by RMB 49.81 million during 2025, reaching a year-end balance of RMB 221.61 million.

2. Business Developments and Risk Factors

• Main Business: The principal activity remains pharmaceutical product distribution in China.
• Key Risks:
  • Supplier and Product Quality: The Group has limited control over suppliers and product quality, which could impact performance if suppliers fail to deliver compliant products.
  • Financial Instrument Risks: The Group faces market risks (primarily exchange rate and interest rate risks), credit risks (with significant concentration among top five customers, accounting for 41.63% of total receivables), and liquidity risks. Management has policies in place to mitigate these risks.
  • Impairment of Receivables: As at year-end, accounts receivable stood at RMB 1,277.44 million (gross), with bad debt provisions of RMB 34.35 million.
• Charity and ESG: The Group contributed RMB 3.43 million to charity and public welfare during the year, reflecting its commitment to ESG principles.

3. Corporate Governance and Shareholder Rights

• Corporate Governance: The Company complies with all applicable provisions of the Hong Kong Stock Exchange Corporate Governance Code and regularly reviews its practices to enhance standards and meet rising regulatory and shareholder expectations.
• Board Composition: The Board includes independent non-executive Directors who have confirmed their independence, and all Directors have completed mandatory training covering duties, ESG, risk management, and industry topics.
• Shareholder Participation: Shareholders holding 10% or more voting shares can request extraordinary general meetings. Those holding over 3% can submit resolutions 10 days before a general meeting.
• Constitutional Changes: Amendments were approved in 2025 to align the Articles of Association with updated Listing Rules and PRC Company Law, including provisions for online participation in shareholder meetings, enhanced minority shareholder protection, and the transfer of supervisor functions to the Audit Committee.
• Public Float: The Company maintained the minimum prescribed public float of at least 25% for H shares throughout 2025.

4. Related Party Transactions and Auditor Confirmation

• Connected Transactions: The New Framework Loan Agreement, Framework Sales, and Purchase Agreements with controlling shareholders were approved, with total loan caps set at RMB 500 million. The auditor has issued an unqualified conclusion confirming no breaches of annual caps.
• Independent Director Review: Independent non-executive Directors confirmed that continuing connected transactions were conducted on normal commercial terms and were fair and reasonable.
• Material Contracts: No material contracts were entered into with controlling shareholders outside the approved framework agreements.
• Contingencies: The Group reported no significant contingent liabilities or commitments requiring disclosure as at year-end.

5. Shareholding and Capital Structure

• Share Capital: Total issued H shares stood at 108,000,000 as of December 31, 2025. No treasury shares were held at year-end.
• Director Holdings: Vice Chairman Yao Chuanglong held 34,530,000 H shares (31.97% of issued H shares).
• Shareholder Rights: No provisions for pre-emptive rights exist under the Articles or PRC law.
• No Equity-linked Agreements: The Group had no equity-linked agreements during 2025.
• Purchase, Sale, Redemption: No purchase, sale, or redemption of listed securities occurred during the year.

6. Audit Opinion and Key Audit Matters

• Unqualified Audit Opinion: Pan-China Certified Public Accountants LLP issued an unqualified opinion, confirming the financial statements fairly reflect the Group’s financial position and results.
• Key Audit Matters:
  • Impairment of Accounts Receivable: Due to the materiality and management judgment involved in impairment testing, this was highlighted as a key audit matter.
  • Inventory Write-down: Adequacy of inventory write-down provisions was also examined.
• Other Information: Auditors confirmed no material misstatements in other information in the annual report.

7. Post-reporting Period Events

• Dividend Distribution: The proposed dividend (RMB 0.30 per share) is subject to shareholder approval. If the total share capital changes before implementation, the total allocation will remain unchanged and individual entitlements will be adjusted accordingly.
• No Material Events: No significant events requiring disclosure occurred after the reporting period.

8. Other Investor-Relevant Information

• Charity Donations: The Group donated RMB 3.43 million to charity and public welfare undertakings in 2025.
• Segment Information: The Company treats pharmaceutical distribution as a single segment for management purposes; no segment breakdown is provided.
• Shareholder Communication: The Board considers its communication policy effective and maintains transparency via annual reports, announcements, and its website.

Potential Price Sensitive Highlights

• Dividend Proposal: The final dividend proposal, if approved, will be a direct return to shareholders and may influence share price.
• Decline in Net Profit: The decrease in net profit compared to the prior year may affect investor sentiment.
• Receivables Risk: High concentration among a few customers and sizeable accounts receivable may be viewed as a risk factor.
• Corporate Governance Amendments: Changes to the Articles of Association to enhance minority shareholder protection and online participation may positively impact governance perceptions.
• Connected Transactions: Confirmation from the auditor and directors that connected transactions were conducted fairly may reduce concerns over related party risks.
• No Material Contingencies: Absence of significant liabilities or litigation is a positive signal.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell securities. Please refer to the official annual report and consult a qualified financial advisor before making investment decisions. All financial data is based on the audited consolidated statements for the year ended December 31, 2025.

View CHARMACY PHAR Historical chart here